Clinical Trial: Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSi
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs & symptoms of blepharitis and tear cytokine and eyelid bacterial load levels
Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.
Current Primary Outcome: Change in clinical signs and symptoms associated with blepharitis [ Time Frame: 8 weeks ]
Original Primary Outcome: Change in clinical signs and symptoms associated with blepharitis, tear cytokine and eyelid bacterial load levels [ Time Frame: 4 weeks ]
Current Secondary Outcome:
- Standard ocular safety assessments [ Time Frame: 4 weeks ]
- Change in tear cytokine and eyelid bacterial load levels [ Time Frame: 4 Weeks ]
Original Secondary Outcome: Standard ocular safety assessments [ Time Frame: 4 weeks ]
Information By: Merck Sharp & Dohme Corp.
Dates:
Date Received: February 27, 2008
Date Started: March 2008
Date Completion:
Last Updated: September 20, 2011
Last Verified: September 2011
